SMi's 9th Annual Pharmaceutical Microbiology UK Conference

SMi Group 20 - 21 January 2020, London, UK.
Pharmaceutical Microbiology as an industry is projected to see significant advancements in the next five years. This forecast is largely attributed to rapid microbiology testing, which has accounted for $3.5 billion last year, while projected to reach nearly double at $6 billion by 2025, and an estimated CAGR of 8.3% leading up to 2025.

At the very core of pharmaceutical microbiology is the accurate and reliable detection of microorganisms that would otherwise contaminate the pharmaceutical products manufactured. This demand for more rapid methods for detection and identification will be accompanied by equally important areas such as: contamination control strategies and environmental monitoring, process automation, and discussing updates to meet regulatory requirements.

Join us at SMi's 9th Annual Pharmaceutical Microbiology Conference to explore novel and developing technologies that tackle the most pressing challenges and push innovation in world of pharmaceutical microbiology.

At the 9th Annual Pharmaceutical Microbiology Conference, you will gain insight into

Featured speakers include

  • Luis Meirinhos-Soares, GMP Inspector, Infarmed IP
  • Jim Polarine, Senior Technical Service Manager, STERIS Corporation
  • Tim Eaton, Sterile Manufacturing Specialist, AstraZeneca
  • Pratixa Patel, Senior Director, Microbiology and Stability Sciences, GSK
  • Ian Symonds, Pharmaceutical Consultant, SDA Pharma
  • Michael Song, Senior Manager, MedImmune
  • Maria Jose Zafra-Domene, Microbiology QC Team Leader, MeiraGTx
  • Ingo Spreitzer, Deputy Head Section Microbial Safety, Paul Ehrlich Institute

Key highlights include for 2020

  • Discuss the regulatory expectations and supportive guidance on bio-contamination control and monitoring in aseptic manufacturing of sterile products from PHSS
  • Gain valuable insight from key opinion leaders in a panel discussion on the impact of the Annex 1 revisions on pharmaceutical microbiology
  • Examine the common myths and urban legends in the pharmaceutical industry related to contamination control from STERIS
  • Explore container closure integrity and controls strategies ensuring product sterility from AstraZeneca
  • Revisit the role of the Official Medicines Control Laboratories as the GMP back up from Infarmed IP

View the full agenda: www.pharma-microbiology.com/wpnWL

Early Bird - Rates

  • Book by 31st October and Save £200
  • Book by 29th November and Save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...